What is Kenneth C. Frazier’s role at Eikon Therapeutics related to this Form 4 filing?

In this Form 4, Kenneth C. Frazier is identified as a director of Eikon Therapeutics. The filing shows his open-market purchase of company common stock and confirms the holdings are reported as direct ownership following the transaction.

Eikon Therapeutics (EIKN) director buys 111,111 shares in open market

Q: What insider transaction did Eikon Therapeutics (EIKN) report for February 4, 2026?

Eikon Therapeutics reported that director Kenneth C. Frazier purchased 111,111 shares of common stock on February 4, 2026 . The transaction was an open-market purchase at a price of $18 per share , increasing his direct holdings.

Q: How many Eikon Therapeutics shares did Kenneth C. Frazier buy and at what price?

Kenneth C. Frazier bought 111,111 shares of Eikon Therapeutics common stock at $18 per share . This open-market purchase on February 4, 2026 resulted in total direct ownership of 111,111 shares after the transaction.

Q: Is the Eikon Therapeutics insider transaction a buy or sell by the director?

The transaction is a buy . Director Kenneth C. Frazier executed an open-market purchase of 111,111 shares of Eikon Therapeutics common stock at $18 per share on February 4, 2026 , classified with transaction code P.

Q: How many Eikon Therapeutics shares does Kenneth C. Frazier own after the reported transaction?

After the reported transaction, Kenneth C. Frazier beneficially owns 111,111 shares of Eikon Therapeutics common stock. The Form 4 indicates this amount as his directly held share balance following the February 4, 2026 open-market purchase.

Filing Impact

(High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

Eikon Therapeutics director Kenneth C. Frazier bought 111,111 shares of the company’s common stock in an open-market transaction. The purchase took place on February 4, 2026 at a price of $18 per share, and he now directly holds 111,111 shares.

Insider Trade Summary

Net Buyer: 111,111 shares

Net Buy 1 txn

Insider FRAZIER KENNETH C

Role Director

Bought 111,111 shs ($2.00M)

Type	Security	Shares	Price	Value
Purchase	Common Stock	111,111	$18.00	$2.00M

Holdings After Transaction: Common Stock — 111,111 shares (Direct)

FAQ

What insider transaction did Eikon Therapeutics (EIKN) report for February 4, 2026?

Eikon Therapeutics reported that director Kenneth C. Frazier purchased 111,111 shares of common stock on February 4, 2026. The transaction was an open-market purchase at a price of $18 per share, increasing his direct holdings.

How many Eikon Therapeutics shares did Kenneth C. Frazier buy and at what price?

Kenneth C. Frazier bought 111,111 shares of Eikon Therapeutics common stock at $18 per share. This open-market purchase on February 4, 2026 resulted in total direct ownership of 111,111 shares after the transaction.

Is the Eikon Therapeutics insider transaction a buy or sell by the director?

The transaction is a buy. Director Kenneth C. Frazier executed an open-market purchase of 111,111 shares of Eikon Therapeutics common stock at $18 per share on February 4, 2026, classified with transaction code P.

How many Eikon Therapeutics shares does Kenneth C. Frazier own after the reported transaction?

After the reported transaction, Kenneth C. Frazier beneficially owns 111,111 shares of Eikon Therapeutics common stock. The Form 4 indicates this amount as his directly held share balance following the February 4, 2026 open-market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/06/2026 - 06:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRAZIER KENNETH C

(Last)

(First)

(Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE

94030

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/04/2026		P		111,111	A	$18	111,111	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

	/s/ Benjamin Thorner, Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR